Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

FDA Schedules Biosimilar Biological Product Development Type 2a Meeting With AEON Biopharma Regarding ABP-450

Author: Benzinga Newsdesk | October 01, 2025 08:10am

- Meeting date aligns with prior guidance -

- FDA to review AEON's analytical development plan and initial data -

Posted In: AEON